VTAMA Cream Shows 49.5% Response Rate in Pediatric Atopic Dermatitis Patients Without Comorbidities
核心洞察
New sub-analysis data from Phase 3 ADORING trials demonstrate that VTAMA (tapinarof) cream achieved a 49.5% vIGA-AD response rate in children aged 2-17 without atopic comorbidities, compared to 14.8% with vehicle (p<0.0001).
Early improvements in skin clearance were observed as early as week 1 and sustained through week 8, with significant benefits in eczema (搜索) severity, sleep quality, and itch control regardless of comorbidity status.
The treatment showed a favorable safety profile with most common adverse events including folliculitis (7.8%), upper respiratory tract infection (4.6%), and headache (3.7%) in the pediatric population.
Organon has announced promising new data for VTAMA (tapinarof) cream in pediatric atopic dermatitis (搜索) patients, with a sub-analysis of Phase 3 trials showing significant efficacy across multiple clinical measures. The data, presented at the 2025 American College of Allergy, Asthma (搜索) & Immunology Annual Scientific Meeting, demonstrate early and consistent responses in children aged 2-17 with moderate to severe atopic dermatitis.
Strong Response Rates Across Patient Populations
The sub-analysis of 654 children from the pivotal ADORING 1 and ADORING 2 trials revealed notable differences in treatment response based on comorbidity status. Children without atopic comorbidities achieved a 49.5% vIGA-AD response rate with VTAMA cream compared to 14.8% with vehicle (p<0.0001). Those with comorbidities such as asthma (搜索), allergic rhinitis (搜索), and food allergies (搜索) showed a 42.3% response rate versus 11.8% with vehicle (p<0.0001).
"These reassuring data show tapinarof cream provided early relief, including on bothersome symptoms such as itch, for children as young as 2 years of age with and without comorbidities," said Dr. Luz Fonacier, Professor of Medicine and Section Head of Allergy at NYU Grossman Long Island School of Medicine.
Rapid Onset and Sustained Benefits
The treatment demonstrated rapid onset of action, with significant improvements in skin clearance observed as early as week 1 and maintained through week 8. Eczema (搜索) severity, measured by EASI scores, improved as early as week 2 and was sustained through the study period. Children without comorbidities achieved a 63.1% EASI-75 response rate compared to 20.4% with vehicle (p<0.0001), while those with comorbidities showed a 54.5% response rate versus 21.8% with vehicle (p<0.0001).
Patient-reported outcomes showed equally impressive results. Total POEM scores improved significantly in both groups, with children without comorbidities achieving a mean score of 6.7 with VTAMA cream versus 11.9 with vehicle (p<0.0001). Sleep quality, measured by POEM sleep scores, also improved substantially, with children without comorbidities scoring 0.6 with VTAMA cream compared to 1.4 with vehicle (p<0.0001).
Itch Control and Quality of Life Improvements
Clinically meaningful improvements in itch, defined as a ≥4-point Peak Pruritus-Numeric Rating Scale response, were observed at week 2 and continued through week 8. Children without comorbidities showed a 63.3% response rate compared to 29.2% with vehicle (p<0.0001), while those with comorbidities achieved a 55.6% response rate versus 36.3% with vehicle (p=0.0043).
Dr. Druhan Howell, a pediatric allergist and immunologist at Coastal Allergy & Asthma (搜索), emphasized the clinical significance of these improvements: "When we're seeing itch control, disease state control with our vIGAs, remaining low, that is important to be talking about with our patients and families, because that is quite frankly different than a lot of the other therapies we've had in the past for atopic dermatitis (搜索)."
Safety Profile in Pediatric Population
The safety analysis of children aged 2-17 in the ADORING trials showed a favorable profile consistent with the prescribing information. The most frequently reported treatment-emergent adverse events were folliculitis (7.8%), upper respiratory tract infection (4.6%), and headache (3.7%).
"I haven't had many people come back and respond that they have had or have seen these safety signals personally," noted Dr. Howell. "That doesn't mean I won't in the future, but at least in the present, I haven't."
Clinical Development Program and Regulatory Status
The ADORING program consisted of two 8-week pivotal trials (ADORING 1 and ADORING 2) and ADORING 3, a 48-week open-label extension trial. In December 2024, the FDA approved VTAMA cream for topical treatment of atopic dermatitis (搜索) in adults and pediatric patients 2 years and older, expanding on its previous approval for plaque psoriasis (搜索) in adults in May 2022.
"This study represents the largest pediatric data set to date for VTAMA," said Dr. Rafael Chaves Cardona, Head of U.S. Medical Affairs and Outcomes Research at Organon. "When added to the wealth of data from the pivotal trials, as well as the ADORING 3 open-label, long-term extension trial, these findings support Organon's commitment to offering treatment options with a favorable safety and efficacy profile for children 2 years and older."
Treatment Convenience and Long-term Benefits
The improvements were sustained with treatment-free intervals up to 80 days, offering significant relief for families managing multiple daily therapies. Dr. Howell highlighted the revolutionary impact on clinical practice: "To be able to say, 'Hey, I can make your skin clear, we can keep it clear, and we're not going to have to apply medicine every day.'"
The sleep improvements also translate to broader quality of life benefits for entire families. "When little kids don't sleep, nobody sleeps, right?" Dr. Howell explained. "And for older children, you have to think that poor quality of sleep is affecting their academic performance... when we're getting good-quality sleep again, everything else kind of improves as a consequence of that."